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Antigen Presentation and the Birbeck Granules of Langerhans Cells 
Since 1961, when Birbeck granules in Langerh ans cell s were first 
observed, inves tiga tors have tried to determine their o ri gin and 
function. In this issue, Daniel i-lanau , Michel Fabre, Didier Albert 
Schmitt, j ean-Luc Stampf, j ean-Claude Gara ud, T homas Bieber, 
Edouard Grosshans, C laude Benezra, and j ean-Pi erre Cazenave 
of INSEHM and of the Universite Louis Pasteur in Stras bourg, 
France, present evidence in support of the hypothesis that the 
granules result from endocytosis. If this hypothesis is correct, it 
is thou ght that Birbeck granules may be necessa ry for processing 
of antigens by Langerhans cells. 
Birbeck granules, which are bilayered membranous structures 
with a bulbous dil atation at one end, are found in the cytoplasm 
of Langerhans cells and are thought to be unique to Langerhans 
and related cells. Inves tiga tors have proposed two possible origins 
for the granules . According to one school of thought, Birbeck 
granules are part of the cell secretory process. They are next to 
the Golgi apparatus, which secretes proteins from the cell , and 
so it is proposed that Birbeck granules originate near the Golgi , 
travel to the cell periphery, attach to the cell membrane, and 
release proteins. The other hypothesis is that the Birbeck granules 
arise from endocytosis-they res ult from an infolding of the cell 
membrane-and they enable the Langerhans cell s to take in sub-
stances from the outside the cell s. 
In support of the endocytosis hypothesis, Gerold Schuler and 
his colleagues at the University of Innsbruck in Austria noti ced 
several yea rs ago that the granules are coa ted with clathrin-a 
protein that lines "coa ted pits," which are pits on the surfaces of 
cells that enter the cells by endocytosis. N ow, Hanau and his 
colleagues present more definiti ve evidence in [lvo r of endocy-
tosis. 
The resea rchers labeled T 6 anti gen-a cell-surface marker for 
Langerh ans and certain other cells- and showed that the labeled 
antigen ca me into the cell throu gh endocytosis. Then, they ob-
served labeled T6 antigen in Birbeck granules . The authors pro-
pose that T6 antigens are brought into Langerhans cells in the 
form of Birbeck granul es. 
The results add further support for the argument that Lang-
erhans cells are antigen-presenting cell s in the skin. It is known 
that anti gen-presenting cells elsewhere have to process protein 
antigens before presenting them to T cells. This processing is 
poorly understood, but it is known that the pro tein antigens have 
to be metabolicall y altered, i. e., they must be cleaved into small 
fragments or unfolded. i-lanau and his co lleagues suggest that 
Birbeck granules, through their role in end ocy tosis, might be 
involved in anti gen processing by Langerh ans cells. 
Combined Interferons 111 Cancer Treatment 
Although many inves tiga tors have conducted clinical studies of 
alpha or gamma interferon in cancer patients, very few have 
looked for combined effects of the two interferons. Yet, says 
Stephen K. Tyring of the Uni versity of Alabama in Birmingham, 
alpha and gamma interferon together may be far more effective 
against malignant cells than either alone. Tyring and his associates 
Catherine Albrecht, Miriam Brysk, Hobert Fleischmann , and 
Samuel Baron report results of in vitro studies of the two inter-
ferons in this issue. 
The investigators looked at the cytotoxic effects of mouse al-
pha/beta and mouse gamma interferon both combined and sep-
arately. In their experiments, they exposed mouse epidermal cells 
that were normal , those that had been exposed to a tumor pro-
motor but were not yet transformed to mali gnancy, and those 
that were transformed. They found that although both types of 
interferon had some cytotoxic effects on the three types of cells, 
neither was parti cul arly effective in causing cell death . But when 
Tyring and his colleagues combined the two interferons, they 
found that together the interferons were quite effective at killing 
the malignancy and transformed 'cell s but were less effective at 
killin g normal cells. These effects, of course, are ideal for cancer 
therapy. 
In add ition, Tyring reports that the effects of the combined 
interferons are even more pronounced when he adds spleen cells, 
which are cytotoxic effector cells. In fact , the combination of 
spleen cell s and the two interferons was suffi cient to completely 
destroy the nl.ali gnancy and promoted cells in his assay . These 
results , according to Tyring, indica te that a combination of alpha 
and gamma interferon might be parti cularly effective in vivo as 
well as in vitro. 
Langerhans Cells and AIDS 
For the first time, accordin g to Troy Daniels, there is a cl ea r 
demonstration of an in situ role of Langerhans cell s and viruses 
corresponding to previous demonstrations of such a rol e in vitro. 
Langerhans cells apparently can keep Epstein-Barr viruses and 
papillomaviruses in check. Daniels and his colleagues Deborah 
Greenspan, J ohn Greenspan , EvelYlle Lellllette, M o rten Schi0dt, 
Vibeke Petersen, and Yvonne de Souza of the University of Ca l-
ifornia in San Francisco report their evidence for this role of 
Langerh ans cells in this issue. 
Daniels previously reported that there are regional differences 
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in the no rmal distribution of Langerhans cells in cells of the oral 
mucosa, so he decided to inves tigate the distribution of Lang-
erhans cells in oral mucosal tissue of patients with hairy leuko-
plakia. These lesions were first observed in 1982 in AI DS patients 
and so fa r have only been seen in patients w ith HIV infections. 
" The occurrence of hairy leukoplakia is thought to be unique to 
people w ho have been exposed to HIV," D aniels says. In fac t, 
there are som e AIDS patients in whom hairy leukoplakia is the 
first manifestation of their disease. 
H airy leuko plakia lesions contain Epstein-Barr virus and pap-
illomavirus antigen and these viruses apparently are involved in 
the etiology of the lesions. Deborah Greenspan has shown that 
hairy leukoplakia is improved w hen patients are trea ted with 
antiviral therapy but the lesions return as soon as the antiviral 
therapy is sto pped . 
THE JO U RNA L OF INVESTIGAT IVE DERMATOLOGY 
When Daniels and his colleagues looked at the distribution of 
Langerhans cell s in patients with hairy leukoplakia, they fo und 
that Langerhans cells were ei ther absent or were present in greatly 
reduced numbers in the hairy leukoplakia lesions, although they 
were present in normal amounts "on the o ther side of the teeth-
in the cheek mucosa," Daniels says. Moreover, Daniels and his 
associates found that there is a correlation with the absence of 
Langerhans cells and the presence of Epstein-Barr virus or pap-
illomavirus antigen in the epithelium of patients. 
O ne possible explanation of these results is that Langerham 
cells are destroyed by the AIDS virus and , w ithout Langerhans 
cells, E pstein-Barr virus and papilloma virus can grow . If this is 
so, it may be that Langerhans cells also are absent fro m other 
mucosal and skin infections in AID S patients and that a lack of 
Langerh ans cells plays a role in these o ther infectio ns. 
A N ew Topical Antiandrogen 
Barbara Nuck and Anne Lucky report in this issue that they have 
begun studies of a compound that acts topicall y as an antiandro-
gen. T he compound, epitestosterone, appears to bind to and block 
the testosterone receptor and , according to Lucky, most likely is 
not toxic. 
Lucky says she began studying epitestosterone, w hich is the 
17et-hydroxy epimer of testosterone, because there is a clinical 
need for a topical antiandrogen for the treatment of acne, hir-
sutism, and hair loss, all of which are androgen-dependent. Al-
th ough there are a number of systemic trea tments for these con-
ditions, "everyone is wary of blocking all the androgens in the 
body," Lucky says . For that reason, she continues, " there has 
been a real push to develop a topical product. " 
Luck y chose to study epites tosterone because it so closely re-
sembles testosterone itself. The onl y difference between the twO 
is in the direction that that one of the hydrogen atom s faces . Yet, 
says Lucky, " that switch changes the compound from a potent 
to an impotent androgen." 
When Lucky and Nuck tes ted epitestosterone by in planting it 
on the fl ank of ham sters, they found that there was a significant 
inhibition of the testosterone-dependent stimulation of pigment, 
sebaceous glands, and hair follicles. "It seems to be the ideal anti-
and rogen," Lucky says. But her work is quite preliminary. "The 
question is w hether it is potent enough or promising enough to 
develop into something that could work clinically," she remarks. 
